Angela J Rogers1, Jiazhen Guan2, Anna Trtchounian2, Gary M Hunninghake2, Rajani Kaimal3, Manisha Desai3, Lori-Ann Kozikowski4, Lesley DeSouza4, Susan Mogan5, Kathleen D Liu6,7, Michael A Matthay6,7, Jay Steingrub4, Art Wheeler5, Joo Heon Yoon8, Kiichi Nakahira9, Augustine M Choi9, Rebecca M Baron2. 1. Division of Pulmonary and Critical Care Medicine, Stanford University, Stanford, CA. 2. Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA. 3. Quantitative Sciences Unit, Department of Medicine, Stanford University, Stanford, CA. 4. Division of Pulmonary and Critical Care Medicine, University of Massachusetts Medical School-Baystate, Springfield, MA. 5. Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University, Nashville, TN. 6. Department of Medicine, Cardiovascular Research Institute, University of California, San Francisco, CA. 7. Department of Anesthesia, Cardiovascular Research Institute, University of California, San Francisco, CA. 8. Department of Otorhinolaryngology, Yonsei University College of Medicine, Seoul, Republic of Korea. 9. Department of Medicine, Weill Cornell Medicine, New York, NY.
Abstract
OBJECTIVE: A high plasma level of inflammasome mediator interleukin-18 was associated with mortality in observational acute respiratory distress syndrome cohorts. Statin exposure increases both inflammasome activation and lung injury in mouse models. We tested whether randomization to statin therapy correlated with increased interleukin-18 in the ARDS Network Statins for Acutely Injured Lungs from Sepsis trial. DESIGN: Retrospective analysis of randomized controlled clinical trial. SETTING: Multicenter North American clinical trial, the ARDS Network Statins for Acutely Injured Lungs from Sepsis. PATIENTS: Six hundred eighty-three subjects with infection-related acute respiratory distress syndrome, representing 92% of the original trial population. INTERVENTIONS: Random assignment of rosuvastatin or placebo for up to 28 days or 3 days after ICU discharge. MEASUREMENTS AND MAIN RESULTS: We measured plasma interleukin-18 levels in all Statins for Acutely Injured Lungs from Sepsis patients with sample available at day 0 (baseline, n = 683) and day 3 (after randomization, n = 588). We tested the association among interleukin-18 level at baseline, rising interleukin-18, and the impact of statin therapy on 60-day mortality, adjusting for severity of illness. Baseline plasma interleukin-18 level greater than or equal to 800 pg/mL was highly associated with 60-day mortality, with a hazard of death of 2.3 (95% CI, 1.7-3.1). Rising plasma interleukin-18 was also associated with increased mortality. For each unit increase in log2 (interleukin-18) at day 3 compared with baseline, the hazard of death increased by 2.3 (95% CI, 1.5-3.5). Subjects randomized to statin were significantly more likely to experience a rise in plasma interleukin-18 levels. Subjects with acute kidney injury, shock, low baseline interleukin-18, and those not receiving systemic corticosteroids were more likely to experience rising interleukin-18. Randomization to statin therapy was associated with rising in interleukin-18 in all of those subsets, however. CONCLUSIONS: Elevated baseline plasma interleukin-18 was associated with higher mortality in sepsis-induced acute respiratory distress syndrome. A rise in plasma interleukin-18 was also associated with increased mortality and was more common in subjects randomized to statin therapy in this clinical trial.
RCT Entities:
OBJECTIVE: A high plasma level of inflammasome mediator interleukin-18 was associated with mortality in observational acute respiratory distress syndrome cohorts. Statin exposure increases both inflammasome activation and lung injury in mouse models. We tested whether randomization to statin therapy correlated with increased interleukin-18 in the ARDS Network Statins for Acutely Injured Lungs from Sepsis trial. DESIGN: Retrospective analysis of randomized controlled clinical trial. SETTING: Multicenter North American clinical trial, the ARDS Network Statins for Acutely Injured Lungs from Sepsis. PATIENTS: Six hundred eighty-three subjects with infection-related acute respiratory distress syndrome, representing 92% of the original trial population. INTERVENTIONS: Random assignment of rosuvastatin or placebo for up to 28 days or 3 days after ICU discharge. MEASUREMENTS AND MAIN RESULTS: We measured plasma interleukin-18 levels in all Statins for Acutely Injured Lungs from Sepsispatients with sample available at day 0 (baseline, n = 683) and day 3 (after randomization, n = 588). We tested the association among interleukin-18 level at baseline, rising interleukin-18, and the impact of statin therapy on 60-day mortality, adjusting for severity of illness. Baseline plasma interleukin-18 level greater than or equal to 800 pg/mL was highly associated with 60-day mortality, with a hazard of death of 2.3 (95% CI, 1.7-3.1). Rising plasma interleukin-18 was also associated with increased mortality. For each unit increase in log2 (interleukin-18) at day 3 compared with baseline, the hazard of death increased by 2.3 (95% CI, 1.5-3.5). Subjects randomized to statin were significantly more likely to experience a rise in plasma interleukin-18 levels. Subjects with acute kidney injury, shock, low baseline interleukin-18, and those not receiving systemic corticosteroids were more likely to experience rising interleukin-18. Randomization to statin therapy was associated with rising in interleukin-18 in all of those subsets, however. CONCLUSIONS: Elevated baseline plasma interleukin-18 was associated with higher mortality in sepsis-induced acute respiratory distress syndrome. A rise in plasma interleukin-18 was also associated with increased mortality and was more common in subjects randomized to statin therapy in this clinical trial.
Authors: Thelma R Craig; Martin J Duffy; Murali Shyamsundar; Cliona McDowell; Cecilia M O'Kane; J Stuart Elborn; Daniel F McAuley Journal: Am J Respir Crit Care Med Date: 2010-09-24 Impact factor: 21.405
Authors: D Novick; B Schwartsburd; R Pinkus; D Suissa; I Belzer; Z Sthoeger; W F Keane; Y Chvatchko; S H Kim; G Fantuzzi; C A Dinarello; M Rubinstein Journal: Cytokine Date: 2001-06-21 Impact factor: 3.861
Authors: M G Netea; G Fantuzzi; B J Kullberg; R J Stuyt; E J Pulido; R C McIntyre; L A Joosten; J W Van der Meer; C A Dinarello Journal: J Immunol Date: 2000-03-01 Impact factor: 5.422
Authors: Peter S Kruger; Meg L Harward; Mark A Jones; Christopher J Joyce; Karam M Kostner; Michael S Roberts; Bala Venkatesh Journal: Am J Respir Crit Care Med Date: 2010-10-19 Impact factor: 21.405
Authors: Reimar W Thomsen; Anders Riis; Jette B Kornum; Steffen Christensen; Søren P Johnsen; Henrik T Sørensen Journal: Arch Intern Med Date: 2008-10-27
Authors: Huiling Wu; Melissa L Craft; Peng Wang; Kate R Wyburn; Gang Chen; Jin Ma; Brett Hambly; Steven J Chadban Journal: J Am Soc Nephrol Date: 2008-09-24 Impact factor: 10.121
Authors: Marius Terblanche; Yaniv Almog; Robert S Rosenson; Terry S Smith; Daniel G Hackam Journal: Lancet Infect Dis Date: 2006-04 Impact factor: 25.071
Authors: Yale Jiang; Brian R Rosborough; Jie Chen; Sudipta Das; Georgios D Kitsios; Bryan J McVerry; Rama K Mallampalli; Janet S Lee; Anuradha Ray; Wei Chen; Prabir Ray Journal: JCI Insight Date: 2020-07-09
Authors: Konrad Peukert; Mario Fox; Susanne Schulz; Caroline Feuerborn; Stilla Frede; Christian Putensen; Hermann Wrigge; Beate Mareike Kümmerer; Sascha David; Benjamin Seeliger; Tobias Welte; Eicke Latz; Dennis Klinman; Christoph Wilhelm; Folkert Steinhagen; Christian Bode Journal: Am J Respir Crit Care Med Date: 2021-07-01 Impact factor: 21.405